Bridgeway Capital Management’s ALX Oncology ALXO Stock Holding History

Bridgeway Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$468K	Buy	226,072 +150,000	+197%	+$268K	0.01%	863
2026 Q1	$153K	Hold	76,072	–	–	﹤0.01%	1079
2025 Q4	$86K	Buy	76,072 +40,072	+111%	+$60.7K	﹤0.01%	1143
2025 Q3	$65.9K	Buy	+36,000	New	+$31.2K	﹤0.01%	1146
2025 Q1	–	Sell	-75,000	Closed	-$125K	–	1178
2024 Q4	$125K	Buy	+75,000	New	+$115K	﹤0.01%	1084
2024 Q2	–	Sell	-20,000	Closed	-$223K	–	1272
2024 Q1	$223K	Sell	20,000 -13,500	-40%	-$190K	﹤0.01%	1088
2023 Q4	$499K	Sell	33,500 -15,000	-31%	-$142K	0.01%	945
2023 Q3	$233K	Hold	48,500	–	–	0.01%	1070
2023 Q2	$364K	Buy	+48,500	New	+$317K	0.01%	997

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Bridgeway Capital Management's ALXO Position: Q2 2026 in Review

Bridgeway Capital Management increased its ALX Oncology (ALXO) stake by 197% in Q2 2026, buying an estimated $268K and bringing the position to 226,072 shares worth $468K. The position accounts for 0.01% of the portfolio, ranked #863.

Bridgeway Capital Management first reported a position in ALXO in Q2 2023 and has held it in 9 quarters since. The position peaked at $499K in Q4 2023. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Bridgeway Capital Management held 226,072 shares of ALX Oncology worth $468K as of Q2 2026.
Bridgeway Capital Management bought 150,000 ALX Oncology shares in Q2 2026, an estimated $268K.
ALX Oncology made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #863 holding.
Bridgeway Capital Management first reported a position in ALX Oncology in Q2 2023 and has held it in 9 quarters since.
Bridgeway Capital Management's ALX Oncology position peaked at $499K in Q4 2023.
94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.